Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01067508
Other study ID # 06-12-097-03
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2007
Est. completion date February 2011

Study information

Verified date May 2019
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this research study is to determine by laboratory analyses the effects of drinking silicon-rich water on bone health. This will be determined from blood and urine samples from subjects who will be asked to drink 1 liter per day of either silicon-rich water or water without silicon for 12 weeks.


Description:

Naturally occurring silicon as aqueous silicic acids at a level of 85 mg/liter which is well within safe intake limits occurs in water obtained from artesian wells in Fiji (Fiji Water, Inc.). Other drinking waters (e.g. Aquafina, Crystal Geyser, etc.) have all trace minerals including silicon removed by reverse osmosis. Silicon may be a necessary mineral for bone health. Therefore, this study aims to demonstrate the potential beneficial effects of short-term intake of silicon-rich water (85 mg/day of silicon in the diet from 1 liter of Fiji Water) compared to deionized water (with no silicon) over 12 weeks in normal postmenopausal women. The women to be studied will be stratified by bone density (based on T score by DEXA) and have analyses of biomarkers of bone metabolism to achieve the following specific aims:

1. To conduct a prospective randomized controlled trial in two mixed groups of 15 normal postmenopausal women and osteopenic pre- and peri-menopausal women receiving either 1 liter per day of FIJI water (A) or 1 liter per day of purified drinking water with no minerals (B). During screening we will ask prospective participants about their menopausal status (where post-menopausal means having no menstrual period for one year), block on their menopausal status, and randomize to either Treatment A or Treatment B. There will be 7-8 post-menopausal women and 7-8 pre- or peri-menopausal women in each group.

2. To determine silicon absorption by measuring urinary silicon excretion

3. To determine bone resorption and turn over markers by measuring urinary N-Telopeptide, serum bone alkaline phosphatase, osteocalcin, procollagen Type I Intact N-Terminal Propeptide, 25 hydroxyvitamin D, parathyroid hormone (PTH) and calcium.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date February 2011
Est. primary completion date December 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Body mass index (BMI) < 30

- Postmenopausal women with no evidence of osteoporosis by dual energy X-ray absorptiometry (DEXA) scan (T = -2 in the total hip and lumbar spine).

- Pre- or peri-menopausal women with osteopenia but no evidence of osteoporosis by DEXA scan (-1.5 = T = -2 in the total hip and lumbar spine)

- No estrogens or corticosteroids

- No prior history of bisphosphonate medication

- Otherwise in good health with no significant illnesses which could affect bone metabolism such as hypercortisolism, untreated hypothyroidism, treatment with statins or other drugs affecting bone metabolism other than calcium and vitamin D3.

- No change in exercise regimen or calcium intake in the past 3 months.

- Subject must sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or randomization. A subject will be excluded for any condition that might compromise the ability to give truly informed consent for participation in the study.

Exclusion Criteria:

- Males

- Premenopausal women with DEXA T scores = -1.5 or = -2.

- Postmenopausal women with DEXA T scores = -2.

Study Design


Intervention

Other:
Fiji Water
Participants are asked to drink one liter of this silicon-rich water daily for three months.

Locations

Country Name City State
United States University of California, Los Angeles Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Silicon Absorption at 12 Weeks Change from baseline in silicon absorption in response to silicon-rich water (Fiji) supplementation for 12 weeks was determined by measuring urinary solicon concentration (mg/mg) normalized to creatinine. 12 Weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02237534 - Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Phase 4
Completed NCT04396288 - Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response N/A
Active, not recruiting NCT04342078 - Vitamin D and Health Outcomes in Preterm Born Population
Completed NCT01820702 - Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation N/A
Active, not recruiting NCT05735197 - Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients Phase 4
Completed NCT01360099 - Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study N/A
Completed NCT00076830 - Evaluation and Treatment of Patients With Connective Tissue Disease
Completed NCT00001916 - Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression N/A
Completed NCT02435329 - Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study
Recruiting NCT04528446 - The Impact of Glomerular Disorders on Bone Quality and Strength
Enrolling by invitation NCT06351176 - Impact of Glycemic Control on Skeletal Outcomes in Adults With Type 1 Diabetes
Recruiting NCT00357331 - The Effects of Potassium Citrate on Bone Metabolism Phase 4
Terminated NCT00504218 - Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients
Recruiting NCT02769975 - Evaluation of Children With Endocrine and Metabolic-Related Conditions
Completed NCT02999204 - Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Phase 4
Completed NCT01108211 - Improving Low Bone Mass With Vibration Therapy in Adolescent Idiopathic Scoliosis (AIS) Phase 3
Completed NCT04093856 - Determinants of Bone and Muscle Quality and Strength in Obesity With and Without Diabetes
Recruiting NCT06368154 - Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity
Active, not recruiting NCT04439747 - Develop and Implement Methods for Diagnostic and Treatment of Hormonal Disorders in Patients With Chronic Kidney Disease
Completed NCT01507662 - Patient Activation After DXA Result Notification N/A